A 22 Gene-expression Assay, Decipher® (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical Prostatectomy

Conclusions The recently introduced genomic classifier was developed to identify men with increased risk for metastatic prostate cancer following radical prostatectomy. The genomic classifier was shown to have good discrimination in detecting men at risk for metastatic prostate cancer five years after surgery (AUC 0.75 to 0.90). However, these estimates may be biased given differences in important prognostic characteristics between cases and controls. Independent validation in patients with high-risk prostate cancer may provide more reliable estimates of the prognostic ability of the genomic classifier. At this time it is unclear what the most appropriate clinical actions are based on test results. No studies yet published have reported the ability of the genomic classifier to predict significant clinical outcomes from any of the available adjuvant therapies. In order to demonstrate clinical utility additional evidence is needed showing improved outcomes (clinical metastasis or prostate cancer-specific mortality) in men whose post-operative treatment was guided by the genomic classifier compared to standard practice. Competing Interests The authors have declared that no competing interests exist. The findings and conclusions are those of authors, including NIH co-authors, and do not necessarily represent the views of the National Institutes of Health (NIH). The information provided in this manuscript does not constitute an endorsement of any of the commercially available te...
Source: PLOS Currents Evidence on Genomic Tests - Category: Genetics & Stem Cells Authors: Source Type: research